gdc
Submit Your Story
Subscribe

Newsworthy

New Developments in Lung Cancer Therapy Reported at Recent Cancer Meetings
Lung CancerNewsworthy
New Developments in Lung Cancer Therapy Reported at Recent Cancer Meetings
By Dana Taylor
November 2018 Volume 4 – Lung Cancer – November 18, 2018
FDA NewsLung CancerNewsworthy
Vizimpro a New First Treatment for Patients with Metastatic Lung Cancer and EGFR Mutations
November 2018 Volume 4 – Lung Cancer – November 17, 2018
Imfinzi First Drug Approved to Reduce Cancer Progression in Stage III Lung Cancer
FDA NewsLung CancerNewsworthy
Imfinzi First Drug Approved to Reduce Cancer Progression in Stage III Lung Cancer
November 2018 Volume 4 – Lung Cancer – November 17, 2018
Gilotrif Approved as First Treatment for Metastatic Lung Cancer and EGFR Mutations
FDA NewsLung CancerNewsworthy
Gilotrif Approved as First Treatment for Metastatic Lung Cancer and EGFR Mutations
November 2018 Volume 4 – Lung Cancer – November 17, 2018
FDA NewsLeukemiaNewsworthy
Tibsovo First Drug Approved by the FDA for AML with IDH1 Mutation
October 2018 Vol 4 No 5 – October 17, 2018
In July 2018, the FDA approved Tibsovo (ivo-sidenib; from Agios Pharmaceuticals), the first IDH1 inhibitor, for the treatment of adults with relapsed (returning) or refractory (not responding to treatment) acute myeloid leukemia (AML) and a susceptible IDH1 genetic mutation.
FDA NewsLung CancerNewsworthy
FDA Approved Opdivo for Metastatic Small-Cell Lung Cancer
October 2018 Vol 4 No 5 – October 17, 2018
FDA NewsLiver CancerNewsworthy
Lenvima a New Option Approved for Initial Treatment of Liver Cancer
October 2018 Vol 4 No 5 – October 17, 2018
Previously approved for thyroid cancer and kidney cancer, the FDA has recently approved Lenvima as the first treatment for patients with liver cancer.
FDA NewsMelanomaNewsworthy
Braftovi plus Mektovi a New Combination for Metastatic Melanoma with BRAF Mutation
October 2018 Vol 4 No 5 – October 17, 2018
FDA NewsKidney CancerNewsworthy
Opdivo plus Yervoy First Immunotherapy Regimen for Initial Treatment of Kidney Cancer
October 2018 Vol 4 No 5 – October 17, 2018
The use of Opdivo with Yervoy is the first immunotherapy combination therapy approved by the FDA for patients with kidney cancer.
Gilotrif Approved as First Treatment for Metastatic Lung Cancer and EGFR Mutations
FDA NewsLung CancerNewsworthy
Gilotrif Approved as First Treatment for Metastatic Lung Cancer and EGFR Mutations
May 2018 Cancer Biomarkers and Molecular Testing – June 28, 2018
Page 1 of 6
Results 1 - 10 of 55

Subscribe to CONQUER: the patient voice® magazine

Receive timely cancer news & updates, patient stories, and more.

Country